Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Prime Medicine, Inc. (PRME – Research Report). The associated price target remains the same with $14.00.
Soumit Roy has given his Buy rating due to a combination of factors that highlight Prime Medicine, Inc.’s innovative approach and promising preclinical results. The company has recently expanded its liver program into the AATD space, utilizing its proprietary prime editing technology and Gal-NAc targeting ligand LNPs to address the E342K mutation in the SERPINA1 gene. This approach is distinguished by the absence of bystander mutations, which is a notable advantage over competitors like Beam’s base editing. Additionally, Prime’s method has demonstrated high levels of normal AAT in mouse models, surpassing peers in the DNA and RNA editing sectors.
Another compelling reason for the Buy rating is Prime’s use of LNP for delivery, which is considered safer compared to the AAV method used by some gene therapy companies, as AAV is linked with significant adverse events. The preclinical data shows promising results, with mouse models achieving serum M-AAT levels between 40µM and 65µM, which are competitive with or exceed those of other companies in the field. Although the candidate optimization is ongoing and human liver results may vary, the expected IND filing in mid-2026 for AATD further supports the potential of Prime’s approach, making it a strong candidate for investment.
According to TipRanks, Roy is an analyst with an average return of -22.5% and a 18.92% success rate. Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Precision BioSciences, and Oric Pharmaceuticals.
In another report released on March 4, JMP Securities also maintained a Buy rating on the stock with a $10.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com